In situ biomolecule production by bacteria; a synthetic biology approach to medicine

Journal of Controlled Release

Volumn 275, Issue , 2018, Pages 217-228

  Flores Bueso, Yensi ^a,b,c   Lehouritis, Panos ^b   Tangney, Mark ^a,b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Drug delivery; Engineering; Gene therapy; Microbiome; Tumour

Indexed keywords

BIOMOLECULES; DIAGNOSIS; DRUG DELIVERY; ENGINEERING; GENE THERAPY; PROGRAM DIAGNOSTICS; TUMORS;

DIAGNOSTIC APPROACH; DIAGNOSTIC DEVICE; ENABLING TECHNOLOGIES; IN-SITU PRODUCTION; MICROBIOME; RESEARCH AND DEVELOPMENT; RESEARCH APPROACH; SYNTHETIC BIOLOGY;

BACTERIA;

DRUG; PEPTIDE; RNA; BIOLOGICAL PRODUCT;

BACTERIAL GROWTH; BACTERIAL STRAIN; BIOENGINEERING; CANCER THERAPY; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; DRUG MARKETING; DRUG TARGETING; HOST CELL; HUMAN; MALIGNANT NEOPLASM; MEDICAL TECHNOLOGY; MEDICINE; MICROBIAL COLONIZATION; MICROFLORA; NEOPLASM; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; SAFETY PROCEDURE; SYNTHETIC BIOLOGY; TREATMENT INDICATION; ANIMAL; BACTERIUM; METABOLISM; MICROBIOLOGY;

ANIMALS; BACTERIA; BIOLOGICAL PRODUCTS; HUMANS; NEOPLASMS; SYNTHETIC BIOLOGY;

EID: 85042480524     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2018.02.023     Document Type: Review

References (119)

1. Cederbaum, S.D., Fareed, G.C., Lovett, M.A., Shapiro, L.J., Recombinant, D.N.A., in medicine. West J. Med. 141 (1984), 210–222 http://www.ncbi.nlm.nih.gov/pubmed/6208695.
2. Keen, H., Glynne, A., Pickup, J.C., Viberti, G.C., Bilous, R.W., Jarrett, R.J., Marsden, R., Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men. Lancet 2 (1980), 398–401 https://www.ncbi.nlm.nih.gov/pubmed/6105520.
3. Paddon, C.J., Keasling, J.D., Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat. Rev. Microbiol. 12 (2014), 355–367, 10.1038/nrmicro3240.
4. Keasling, J.D., Synthetic biology and the development of tools for metabolic engineering. Metab. Eng. 14 (2012), 189–195, 10.1016/j.ymben.2012.01.004.
5. Lee, Y.J., Jeong, K.J., Challenges to production of antibodies in bacteria and yeast. J. Biosci. Bioeng. 120 (2015), 483–490, 10.1016/j.jbiosc.2015.03.009.
6. Zarco, M.F., Vess, T.J., Ginsburg, G.S., The oral microbiome in health and disease and the potential impact on personalized dental medicine. Oral Dis. 18 (2012), 109–120, 10.1111/j.1601-0825.2011.01851.x.
7. Chen, H., Jiang, W., Application of high-throughput sequencing in understanding human oral microbiome related with health and disease. Front. Microbiol., 5, 2014, 508, 10.3389/fmicb.2014.00508.
8. Al-Ghazzewi, F.H., Tester, R.F., Biotherapeutic agents and vaginal health. J. Appl. Microbiol. 121 (2016), 18–27, 10.1111/jam.13054.
9. Kong, H.H., Andersson, B., Clavel, T., Common, J.E., Jackson, S.A., Olson, N.D., Segre, J.A., Traidl-Hoffmann, C., Performing skin microbiome research: a method to the madness. J. Invest. Dermatol. 137 (2017), 561–568, 10.1016/j.jid.2016.10.033.
10. Schwabe, R.F., Jobin, C., The microbiome and cancer. Nat. Rev. Cancer 13 (2013), 800–812, 10.1038/nrc3610.
11. Viaud, S., Daillere, R., Boneca, I.G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M.J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., Zitvogel, L., Gut microbiome and anticancer immune response. Cell Death Differ., 2014, 10.1038/cdd.2014.56.
12. Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., Benyamin, F.W., Lei, Y.M., Jabri, B., Alegre, M.L., Chang, E.B., Gajewski, T.F., Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089, 10.1126/science.aac4255.
13. Limaye, S.A., Haddad, R.I., Cilli, F., Sonis, S.T., Colevas, A.D., Brennan, M.T., Hu, K.S., Murphy, B.A., Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119 (2013), 4268–4276, 10.1002/cncr.28365.
14. Byrne, W.L., Tangney, M., Bacteria as gene therapy vectors for cancer. Smyth Templeton, N., (eds.) Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 2015, CRC Press.
15. Schmidt, I., van Spanning, R.J.M., Jetten, M.S.M., Denitrification and ammonia oxidation by Nitrosomonas europaea wild-type, and NirK- and NorB-deficient mutants. Microbiology 150 (2004), 4107–4114, 10.1099/mic.0.27382-0.
16. Murphy, C., Rettedal, E., Lehouritis, P., Devoy, C., Tangney, M., Intratumoural production of TNFα by bacteria mediates cancer therapy. PLoS One, 12, 2017, e0180034, 10.1371/journal.pone.0180034.
17. Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., Cuvelier, C., Rottiers, P., Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol., 3, 2009, 49, 10.1038/mi.2009.116.
18. Deplazes, A., Piecing together a puzzle. An exposition of synthetic biology. EMBO Rep. 10 (2009), 428–432, 10.1038/embor.2009.76.
19. Endy, D., 2003 synthetic biology study. 2003 Synthetic Biology Study, 2007, MIT, 18 http://hdl.handle.net/1721.1/38455.
20. Endy, D., Foundations for engineering biology. Nature 438 (2005), 449–453, 10.1038/nature04342.
21. Elowitz, M.B., Leibler, S., A synthetic oscillatory network of transcriptional regulators. Nature 403 (2000), 335–338, 10.1038/35002125.
22. Gardner, T.S., Cantor, C.R., Collins, J.J., Construction of a genetic toggle switch in Escherichia coli. Nature 403 (2000), 339–342, 10.1038/35002131.
23. Newcomb, J., Carlson, R., Aldrich, S.C., Genome synthesis and design futures: implications for the U.S. economy. Bio-Economic Research Associates (BIO-ERA), 2007, 172 https://bio.org/articles/genome-synthesis-and-design-futures-implications-us-economy.
24. Flores Bueso, Y., Tangney, M., Synthetic biology in the driving seat of the bioeconomy. Trends Biotechnol., 2017, 10.1016/j.tibtech.2017.02.002.
25. Lee, S.K., Chou, H., Ham, T.S., Lee, T.S., Keasling, J.D., Metabolic engineering of microorganisms for biofuels production: from bugs to synthetic biology to fuels. Curr. Opin. Biotechnol. 19 (2008), 556–563, 10.1016/j.copbio.2008.10.014.
26. Gupta, P., Phulara, S.C., Metabolic engineering for isoprenoid-based biofuel production. J. Appl. Microbiol. 119 (2015), 605–619, 10.1111/jam.12871.
27. Wang, B.W., Shi, A.Q., Tu, R., Zhang, X.L., Wang, Q.H., Bai, F.W., Branched-chain higher alcohols. Adv. Biochem. Eng. Biotechnol. 128 (2012), 101–118, 10.1007/10_2011_121.
28. Huffer, S., Roche, C.M., Blanch, H.W., Clark, D.S., Escherichia coli for biofuel production: bridging the gap from promise to practice. Trends Biotechnol. 30 (2012), 538–545, 10.1016/j.tibtech.2012.07.002.
29. Vickers, C.E., Blank, L.M., Kromer, J.O., Grand challenge commentary: chassis cells for industrial biochemical production. Nat. Chem. Biol. 6 (2010), 875–877, 10.1038/nchembio.484.
30. Khalil, A.S., Collins, J.J., Synthetic biology: applications come of age. Nat. Rev. Genet. 11 (2010), 367–379, 10.1038/nrg2775.
31. Petzold, C., Chan, L.J., Nhan, M., Adams, P., Analytics for metabolic engineering. Front. Bioeng. Biotechnol., 3, 2015, 10.3389/fbioe.2015.00135.
32. Liu, R., Bassalo, M.C., Zeitoun, R.I., Gill, R.T., Genome scale engineering techniques for metabolic engineering. Metab. Eng. 32 (2015), 143–154, 10.1016/j.ymben.2015.09.013.
33. Brenner, M.J., Cho, J.H., Wong, N.M.L., Wong, W.W., Synthetic biology: immunotherapy by design. Annu. Rev. Biomed. Eng., 2018, 10.1146/annurev-bioeng-062117-121147.
34. Slusarczyk, A.L., Lin, A., Weiss, R., Foundations for the design and implementation of synthetic genetic circuits. Nat. Rev. Genet. 13 (2012), 406–420, 10.1038/nrg3227.
35. Andrianantoandro, E., Basu, S., Karig, D.K., Weiss, R., Synthetic biology: new engineering rules for an emerging discipline. Mol. Syst. Biol., 2, 2006, 10.1038/msb4100073.
36. Wang, Y.H., Wei, K.Y., Smolke, C.D., Synthetic biology: advancing the design of diverse genetic systems. Ann. Rev. Chem. Biomol. Eng. 4 (2013), 69–102, 10.1146/annurev-chembioeng-061312-103351.
37. Cameron, D.E., Bashor, C.J., Collins, J.J., A brief history of synthetic biology. Nat. Rev. Microbiol. 12 (2014), 381–390, 10.1038/nrmicro3239.
38. Kosuri, S., Church, G.M., Large-scale de novo DNA synthesis: technologies and applications. Nat. Methods 11 (2014), 499–507, 10.1038/nmeth.2918.
39. Esvelt, K.M., Wang, H.H., Genome-scale engineering for systems and synthetic biology. Mol. Syst. Biol., 9, 2013, 641, 10.1038/msb.2012.66.
40. Cambray, G., Mutalik, V.K., Arkin, A.P., Toward rational design of bacterial genomes. Curr. Opin. Microbiol. 14 (2011), 624–630, 10.1016/j.mib.2011.08.001.
41. Purnick, P.E., Weiss, R., The second wave of synthetic biology: from modules to systems. Nat. Rev. Mol. Cell Biol. 10 (2009), 410–422, 10.1038/nrm2698.
42. Mutalik, V.K., Guimaraes, J.C., Cambray, G., Lam, C., Christoffersen, M.J., Mai, Q.A., Tran, A.B., Paull, M., Keasling, J.D., Arkin, A.P., Endy, D., Precise and reliable gene expression via standard transcription and translation initiation elements. Nat. Methods 10 (2013), 354–360, 10.1038/nmeth.2404.
43. Whitaker, W.R., Davis, S.A., Arkin, A.P., Dueber, J.E., Engineering robust control of two-component system phosphotransfer using modular scaffolds. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 18090–18095, 10.1073/pnas.1209230109.
44. Keung, A.J., Joung, J.K., Khalil, A.S., Collins, J.J., Chromatin regulation at the frontier of synthetic biology. Nat. Rev. Genet. 16 (2015), 159–171, 10.1038/nrg3900.
45. Brophy, J.A., Voigt, C.A., Principles of genetic circuit design. Nat. Methods 11 (2014), 508–520, 10.1038/nmeth.2926.
46. Dominguez, A.A., Lim, W.A., Qi, L.S., Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell Biol. 17 (2016), 5–15, 10.1038/nrm.2015.2.
47. Dueber, J.E., Yeh, B.J., Chak, K., Lim, W.A., Reprogramming control of an allosteric signaling switch through modular recombination. Science 301 (2003), 1904–1908, 10.1126/science.1085945.
48. Bonnet, J., Yin, P., Ortiz, M.E., Subsoontorn, P., Endy, D., Amplifying genetic logic gates. Science 340 (2013), 599–603, 10.1126/science.1232758.
49. Hasty, J., McMillen, D., Collins, J.J., Engineered gene circuits. Nature 420 (2002), 224–230, 10.1038/nature01257.
50. Ozbudak, E.M., Thattai, M., Kurtser, I., Grossman, A.D., van Oudenaarden, A., Regulation of noise in the expression of a single gene. Nat. Genet. 31 (2002), 69–73, 10.1038/ng869.
51. Becskei, A., Serrano, L., Engineering stability in gene networks by autoregulation. Nature 405 (2000), 590–593, 10.1038/35014651.
52. Green, Alexander A., Silver, Pamela A., Collins, James J., Yin, P., Toehold switches: de-novo-designed regulators of gene expression. Cell 159 (2014), 925–939, 10.1016/j.cell.2014.10.002.
53. Isaacs, F.J., Dwyer, D.J., Ding, C., Pervouchine, D.D., Cantor, C.R., Collins, J.J., Engineered riboregulators enable post-transcriptional control of gene expression. Nat. Biotechnol. 22 (2004), 841–847, 10.1038/nbt986.
54. Bayer, T.S., Smolke, C.D., Programmable ligand-controlled riboregulators of eukaryotic gene expression. Nat. Biotechnol. 23 (2005), 337–343, 10.1038/nbt1069.
55. Looger, L.L., Dwyer, M.A., Smith, J.J., Hellinga, H.W., Computational design of receptor and sensor proteins with novel functions. Nature 423 (2003), 185–190, 10.1038/nature01556.
56. Kramer, B.P., Viretta, A.U., Daoud-El-Baba, M., Aubel, D., Weber, W., Fussenegger, M., An engineered epigenetic transgene switch in mammalian cells. Nat. Biotechnol. 22 (2004), 867–870, 10.1038/nbt980.
57. Guet, C.C., Elowitz, M.B., Hsing, W., Leibler, S., Combinatorial synthesis of genetic networks. Science 296 (2002), 1466–1470, 10.1126/science.1067407.
58. Kaern, M., Blake, W.J., Collins, J.J., The engineering of gene regulatory networks. Annu. Rev. Biomed. Eng. 5 (2003), 179–206, 10.1146/annurev.bioeng.5.040202.121553.
59. Atkinson, M.R., Savageau, M.A., Myers, J.T., Ninfa, A.J., Development of genetic circuitry exhibiting toggle switch or oscillatory behavior in Escherichia coli. Cell 113 (2003), 597–607 http://www.ncbi.nlm.nih.gov/pubmed/12787501.
60. Guntas, G., Ostermeier, M., Creation of an allosteric enzyme by domain insertion. J. Mol. Biol. 336 (2004), 263–273 http://www.ncbi.nlm.nih.gov/pubmed/14741221.
61. Park, S.H., Zarrinpar, A., Lim, W.A., Rewiring MAP kinase pathways using alternative scaffold assembly mechanisms. Science 299 (2003), 1061–1064, 10.1126/science.1076979.
62. Bulter, T., Lee, S.G., Wong, W.W., Fung, E., Connor, M.R., Liao, J.C., Design of artificial cell-cell communication using gene and metabolic networks. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 2299–2304 http://www.ncbi.nlm.nih.gov/pubmed/14983004.
63. You, L., Cox, R.S. 3rd, Weiss, R., Arnold, F.H., Programmed population control by cell-cell communication and regulated killing. Nature 428 (2004), 868–871, 10.1038/nature02491.
64. Basu, S., Mehreja, R., Thiberge, S., Chen, M.T., Weiss, R., Spatiotemporal control of gene expression with pulse-generating networks. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 6355–6360, 10.1073/pnas.0307571101.
65. Siuti, P., Yazbek, J., Lu, T.K., Synthetic circuits integrating logic and memory in living cells. Nat. Biotechnol. 31 (2013), 448–452, 10.1038/nbt.2510.
66. Borkowski, O., Gilbert, C., Ellis, T., SYNTHETIC, B.I.O.L.O.G.Y., On the record with E. coli DNA. Science 353 (2016), 444–445, 10.1126/science.aah4438.
67. Tamsir, A., Tabor, J.J., Voigt, C.A., Robust multicellular computing using genetically encoded NOR gates and chemical ‘wires’. Nature 469 (2011), 212–215, 10.1038/nature09565.
68. Din, M.O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L.S., Bhatia, S.N., Hasty, J., Synchronized cycles of bacterial lysis for in vivo delivery. Nature 536 (2016), 81–85, 10.1038/nature18930.
69. Tabor, J.J., Salis, H.M., Simpson, Z.B., Chevalier, A.A., Levskaya, A., Marcotte, E.M., Voigt, C.A., Ellington, A.D., A synthetic genetic edge detection program. Cell 137 (2009), 1272–1281, 10.1016/j.cell.2009.04.048.
70. Teague, B.P., Weiss, R., Synthetic biology. Synthetic communities, the sum of parts. Science 349 (2015), 924–925, 10.1126/science.aad0876.
71. Heinemann, M., Panke, S., Synthetic biology—putting engineering into biology. Bioinformatics 22 (2006), 2790–2799, 10.1093/bioinformatics/btl469.
72. Bradley, R.W., Buck, M., Wang, B., Tools and principles for microbial gene circuit engineering. J. Mol. Biol. 428 ((2016), 862–888, 10.1016/j.jmb.2015.10.004.
73. Cummins, J., Tangney, M., Bacteria and tumours: causative agents or opportunistic inhabitants?. Infect. Agent Cancer, 8, 2013, 11, 10.1186/1750-9378-8-11.
74. Baban, C.K., Cronin, M., O'Hanlon, D., O'Sullivan, G.C., Tangney, M., Bacteria as vectors for gene therapy of cancer. Bioeng. Bugs 1 (2010), 385–394, 10.4161/bbug.1.6.13146.
75. Forbes, N.S., Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10 (2010), 785–794, 10.1038/nrc2934.
76. Urbaniak, C., Gloor, G.B., Brackstone, M., Scott, L., Tangney, M., Reid, G., The microbiota of breast tissue and its association with breast cancer. Appl. Environ. Microbiol. 82 (2016), 5039–5048, 10.1128/AEM.01235-16.
77. Urbaniak, C., Cummins, J., Brackstone, M., Macklaim, J.M., Gloor, G.B., Baban, C.K., Scott, L., O'Hanlon, D.M., Burton, J.P., Francis, K.P., Tangney, M., Reid, G., Microbiota of human breast tissue. Appl. Environ. Microbiol. 80 (2014), 3007–3014, 10.1128/AEM.00242-14.
78. Xuan, C., Shamonki, J.M., Chung, A., Dinome, M.L., Chung, M., Sieling, P.A., Lee, D.J., Microbial dysbiosis is associated with human breast cancer. PLoS One, 9, 2014, e83744, 10.1371/journal.pone.0083744.
79. Banerjee, S., Wei, Z., Tan, F., Peck, K.N., Shih, N., Feldman, M., Rebbeck, T.R., Alwine, J.C., Robertson, E.S., Distinct microbiological signatures associated with triple negative breast cancer. Sci. Rep., 5, 2015, 15162, 10.1038/srep15162.
80. Morrissey, D., O'Sullivan, G.C., Tangney, M., Tumour targeting with systemically administered bacteria. Curr. Gene Ther. 10 (2010), 3–14 http://www.ncbi.nlm.nih.gov/pubmed/20156191.
81. Thornlow, D.N., Brackett, E.L., Gigas, J.M., Van Dessel, N., Forbes, N.S., Persistent enhancement of bacterial motility increases tumor penetration. Biotechnol. Bioeng. 112 (2015), 2397–2405, 10.1002/bit.25645.
82. Ahmad, S., Casey, G., Cronin, M., Rajendran, S., Sweeney, P., Tangney, M., O'Sullivan, G.C., Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen. J. Urol. 186 (2011), 687–693 S0022-5347(11)03552-X (pii) https://doi.org/10.1016/j.juro.2011.03.139.
83. Wood, L.M., Paterson, Y., Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front. Cell. Infect. Microbiol., 4, 2014, 51, 10.3389/fcimb.2014.00051.
84. Low, K.B., Ittensohn, M., Luo, X., Zheng, L.M., King, I., Pawelek, J.M., Bermudes, D., Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans. Methods Mol. Med. 90 (2004), 47–60 https://www.ncbi.nlm.nih.gov/pubmed/14657558.
85. Pizarro-Cerda, J., Tedin, K., The bacterial signal molecule, ppGpp, regulates Salmonella virulence gene expression. Mol. Microbiol. 52 (2004), 1827–1844, 10.1111/j.1365-2958.2004.04122.x.
86. Stritzker, J., Hill, P.J., Gentschev, I., Szalay, A.A., Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. Bioeng. Bugs 1 (2010), 139–145, 10.4161/bbug.1.2.10286.
87. Yu, B., Yang, M., Shi, L., Yao, Y., Jiang, Q., Li, X., Tang, L.H., Zheng, B.J., Yuen, K.Y., Smith, D.K., Song, E., Huang, J.D., Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain. Sci. Rep., 2, 2012, 436, 10.1038/srep00436.
88. Park, S.H., Zheng, J.H., Nguyen, V.H., Jiang, S.N., Kim, D.Y., Szardenings, M., Min, J.H., Hong, Y., Choy, H.E., Min, J.J., RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated salmonella-mediated cancer therapy. Theranostics 6 (2016), 1672–1682, 10.7150/thno.16135.
89. Byrne, W.L., Murphy, C.T., Cronin, M., Wirth, T., Tangney, M., Bacterial-mediated DNA delivery to tumour associated phagocytic cells. J. Control. Release 196 (2014), 384–393, 10.1016/j.jconrel.2014.10.030.
90. Anderson, J.C., Clarke, E.J., Arkin, A.P., Voigt, C.A., Environmentally controlled invasion of cancer cells by engineered bacteria. J. Mol. Biol. 355 (2006), 619–627, 10.1016/j.jmb.2005.10.076.
91. van Pijkeren, J.P., Morrissey, D., Monk, I.R., Cronin, M., Rajendran, S., O'Sullivan, G.C., Gahan, C.G., Tangney, M., A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum. Gene Ther. 21 (2010), 405–416, 10.1089/hum.2009.022.
92. Wang, B., Barahona, M., Buck, M., Engineering modular and tunable genetic amplifiers for scaling transcriptional signals in cascaded gene networks. Nucleic Acids Res. 42 (2014), 9484–9492, 10.1093/nar/gku593.
93. Wang, B., Barahona, M., Buck, M., A modular cell-based biosensor using engineered genetic logic circuits to detect and integrate multiple environmental signals. Biosens. Bioelectron. 40 (2013), 368–376, 10.1016/j.bios.2012.08.011.
94. MacDonald, J.T., Barnes, C., Kitney, R.I., Freemont, P.S., Stan, G.B., Computational design approaches and tools for synthetic biology. Integr. Biol. (Camb.) 3 (2011), 97–108, 10.1039/c0ib00077a.
95. Marchisio, M.A., Stelling, J., Computational design tools for synthetic biology. Curr. Opin. Biotechnol. 20 (2009), 479–485, 10.1016/j.copbio.2009.08.007.
96. Nuyts, S., Van Mellaert, L., Theys, J., Landuyt, W., Bosmans, E., Anne, J., Lambin, P., Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 8 (2001), 1197–1201, 10.1038/sj.gt.3301499.
97. Nguyen, V.H., Kim, H.S., Ha, J.M., Hong, Y., Choy, H.E., Min, J.J., Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res. 70 (2010), 18–23, 10.1158/0008-5472.CAN-09-3453.
98. Ryan, R.M., Green, J., Williams, P.J., Tazzyman, S., Hunt, S., Harmey, J.H., Kehoe, S.C., Lewis, C.E., Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther. 16 (2009), 329–339, 10.1038/gt.2008.188.
99. Camacho, E.M., Mesa-Pereira, B., Medina, C., Flores, A., Santero, E., Engineering Salmonella as intracellular factory for effective killing of tumour cells. Sci. Rep., 6, 2016, 30591, 10.1038/srep30591.
100. Baeshen, M.N., Al-Hejin, A.M., Bora, R.S., Ahmed, M.M., Ramadan, H.A., Saini, K.S., Baeshen, N.A., Redwan, E.M., Production of biopharmaceuticals in E. coli: current scenario and future perspectives. J. Microbiol. Biotechnol. 25 (2015), 953–962, 10.4014/jmb.1412.12079.
101. Huang, C.J., Lin, H., Yang, X., Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J. Ind. Microbiol. Biotechnol. 39 (2012), 383–399, 10.1007/s10295-011-1082-9.
102. Bermudez-Humaran, L.G., Aubry, C., Motta, J.P., Deraison, C., Steidler, L., Vergnolle, N., Chatel, J.M., Langella, P., Engineering lactococci and lactobacilli for human health. Curr. Opin. Microbiol. 16 (2013), 278–283, 10.1016/j.mib.2013.06.002.
103. Felgner, S., Kocijancic, D., Frahm, M., Weiss, S., Bacteria in cancer therapy: renaissance of an old concept. Int. J. Microbiol., 2016, 2016, 8451728, 10.1155/2016/8451728.
104. Gupta, S.K., Shukla, P., Advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications. Crit. Rev. Biotechnol. 36 (2016), 1089–1098, 10.3109/07388551.2015.1084264.
105. Takiishi, T., Cook, D.P., Korf, H., Sebastiani, G., Mancarella, F., Cunha, J.P., Wasserfall, C., Casares, N., Lasarte, J.J., Steidler, L., Rottiers, P., Dotta, F., Gysemans, C., Mathieu, C., Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting Lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells. Diabetes 66 (2017), 448–459, 10.2337/db15-1625.
106. Maurer, J., Jose, J., Meyer, T.F., Autodisplay: one-component system for efficient surface display and release of soluble recombinant proteins from Escherichia coli. J. Bacteriol. 179 (1997), 794–804 https://www.ncbi.nlm.nih.gov/pubmed/9006035.
107. Michon, C., Langella, P., Eijsink, V.G., Mathiesen, G., Chatel, J.M., Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications. Microb. Cell Factories, 15, 2016, 70, 10.1186/s12934-016-0468-9.
108. Manuel, E.R., Blache, C.A., Paquette, R., Kaltcheva, T.I., Ishizaki, H., Ellenhorn, J.D., Hensel, M., Metelitsa, L., Diamond, D.J., Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res. 71 (2011), 4183–4191, 10.1158/0008-5472.CAN-10-4676.
109. Tian, Y., Guo, B., Jia, H., Ji, K., Sun, Y., Li, Y., Zhao, T., Gao, L., Meng, Y., Kalvakolanu, D.V., Kopecko, D.J., Zhao, X., Zhang, L., Xu, D., Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC. Cancer Gene Ther. 19 (2012), 393–401, 10.1038/cgt.2012.12.
110. Lehouritis, P., Springer, C., Tangney, M., Bacterial-directed enzyme prodrug therapy. J. Control. Release 170 (2013), 120–131, 10.1016/j.jconrel.2013.05.005.
111. Lehouritis, P., Stanton, M., McCarthy, F.O., Jeavons, M., Tangney, M., Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria. J. Control. Release 222 (2016), 9–17, 10.1016/j.jconrel.2015.11.030.
112. Rajendran, S., Collins, S., van Pijkeren, J.P., O'Hanlon, D., O'Sullivan, G.C., Tangney, M., Targeting of breast metastases using a viral gene vector with tumour-selective transcription. Anticancer Res. 31 (2011), 1627–1635 (31/5/1627 (pii)).
113. Danino, T., Prindle, A., Kwong, G.A., Skalak, M., Li, H., Allen, K., Hasty, J., Bhatia, S.N., Programmable probiotics for detection of cancer in urine. Sci. Transl. Med., 7, 2015, 289ra284, 10.1126/scitranslmed.aaa3519.
114. Panteli, J.T., Forkus, B.A., Van Dessel, N., Forbes, N.S., Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr. Biol. (Camb.) 7 (2015), 423–434, 10.1039/c5ib00047e.
115. Bryant, L.M., Christopher, D.M., Giles, A.R., Hinderer, C., Rodriguez, J.L., Smith, J.B., Traxler, E.A., Tycko, J., Wojno, A.P., Wilson, J.M., Lessons learned from the clinical development and market authorization of Glybera. Hum. Gene Ther. Clin. Dev. 24 (2013), 55–64, 10.1089/humc.2013.087.
116. Lichty, B.D., Breitbach, C.J., Stojdl, D.F., Bell, J.C., Going viral with cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 559–567, 10.1038/nrc3770.
117. Le, D.T., Wang-Gillam, A., Picozzi, V., Greten, T.F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R.L., Onners, B., Uram, J.N., Laheru, D.A., Lutz, E.R., Solt, S., Murphy, A.L., Skoble, J., Lemmens, E., Grous, J., Dubensky, T. Jr., Brockstedt, D.G., Jaffee, E.M., Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33 (2015), 1325–1333, 10.1200/JCO.2014.57.4244.
118. Brockstedt, D.G., Giedlin, M.A., Leong, M.L., Bahjat, K.S., Gao, Y., Luckett, W., Liu, W., Cook, D.N., Portnoy, D.A., Dubensky, T.W. Jr., Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 13832–13837, 10.1073/pnas.0406035101.
119. Verch, T., Pan, Z.K., Paterson, Y., Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect. Immun. 72 (2004), 6418–6425, 10.1128/IAI.72.11.6418-6425.2004.